ABL1 is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

AFF1 is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

ASXL1 is altered in 6.86% of polycythemia vera patients [2].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

BCR is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains BCR status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains DEK status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains ELL status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and polycythemia vera as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH2 is altered in 1.14% of polycythemia vera patients [2].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and polycythemia vera as inclusion criteria, 1 is phase 1 (1 open) [3].

JAK2 is altered in 90.86% of polycythemia vera patients [2].

JAK2 is an inclusion eligibility criterion in 3 clinical trials for polycythemia vera, of which 0 are open and 3 are closed. Of the trials that contain JAK2 status and polycythemia vera as inclusion criteria, 1 is phase 1/phase 2 (0 open), 1 is phase 2 (0 open), and 1 is phase 3 (0 open) [3].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

MECOM is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains NUP214 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains RPN1 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

RUNX1 is altered in 0.57% of polycythemia vera patients [2].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is altered in 4.0% of polycythemia vera patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [3].